All News

myositis.jpg

Long-Term Survival of Idiopathic Inflammatory Myopathies

d Jack Cush, MD

A single center cohort study analyzed the outcome and survival of idiopathic inflammatory myositis (IIM) patients and showed good 5 and 10 year survival but showed significant declined 15-25 years post-diagnosis.

Read Article
antibody (Keep)

Geo-epidemiology of Autoantibodies in Rheumatoid Arthritis

d Jack Cush, MD

A multinational study of rheumatoid arthritis (RA) patients shows a variety of post-translationally modified anti-modified protein antibodies (AMPA). While AMPA differed in different ethnic populations, their levels correlated with total serum IgG.

Read Article
hospital-13-1518181.jpg

Higher Rehospitalization Rates in Younger SLE Patients

d Jack Cush, MD

A Medicare study shows that young adults with systemic lupus erythematosus (SLE) exhibit very high 30-day rehospitalization rates (36%) that are significantly higher than older SLE patients and age matched non-SLE patients.

Read Article
alopecia,universalis

Does Methotrexate Work in Alopecia Universalis?

d Jack Cush, MD

Alopecia areata totalis (AT) and universalis (AU) are the most severe and difficult to treat forms of alopecia areata (AA).

Read Article
pso.PsA_.NPF_.jpg

Does Biologic Treatment in Psoriasis Reduce the Risk of Psoriatic Arthritis?

d Jack Cush, MD

Retrospective claims analysis shows that psoriasis patients treated with either an IL-12/23 inhibitor or an IL-23 inhibitor had a lower risk of developing incident psoriatic arthritis, compared to TNF inhibitors or IL-17 inhibitors.

Read Article
Study of 21 Downs syndrome pts shows DS to be an autoimmunity-prone state, with a steady-state cytokinopathy, and evidence of hyperactivated CD4 T cells and ongoing activated B cells (CD11c+) - all contribute to a breach in immune tolerance. https://t.co/UUEByfBrqk https://t.co/ekq8AHYlxQ

Links:

Dr. John Cush RheumNow ( View Tweet)
GCA patients with AORTITIS proven by CTA or FDG-PET/CT have higher rates of relapse. Among 82 GCA pts, 78% positive on both CTA & PET. Relapse was seen in 70% in the CTA+/PET+ group & 29% in the CTA-/PET+ (p = 0.019). https://t.co/psA6hywouL https://t.co/WORiBd9Qli

Links:

Dr. John Cush RheumNow ( View Tweet)
New PMR Paradigm Lessons from the clinic, brought to you by RheumNow Live. Join us on March 18 &19, 2023 in Dallas, TX https://t.co/4umv0FvmsQ https://t.co/iFQGIHiIds

Links:

Dr. John Cush RheumNow ( View Tweet)
Does Biologic Treatment in Psoriasis Reduce the Risk of PsA? Retrospective claims analysis shows that psoriasis patients treated with an IL-12/23 inhibitor or an IL-23 inhibitor had a lower risk of developing incident PsA. https://t.co/j73V7zMnkn https://t.co/EhGUXDNNlS

Links:

Dr. John Cush RheumNow ( View Tweet)
My Bum Knee QD Clinic - Lessons from the clinic, brought to you by RhuemNow Live, March 18 &19, 2023 - Dallas, TX https://t.co/nqBiAZsYGY https://t.co/MxhCbrWm3p

Links:

Dr. John Cush RheumNow ( View Tweet)
BRIDGE-PMR a proof-of-concept trial studied 1 dose of IV RTX in 47 PMR pts - at 1 yr, 52% RTX were in GC-free remission (compared to 21% given PBO). Eight (33%) patients in the placebo group and six (26%) in the rituximab group had adverse events https://t.co/yv8ezFN5BJ https://t.co/7FOOPbEIf3

Links:

Dr. John Cush RheumNow ( View Tweet)
Bullous pemphigoid is an autoimmune blistering Dz that may be seen with other hematologic dz - hemophilia A, hypereosinophilic syndrome, autoimmune thrombocytopenia, aplastic anemia, Heme malignancy (MDS, CLL, etc) https://t.co/i8WdA28hYP https://t.co/RsJMt9RTNl

Links:

Dr. John Cush RheumNow ( View Tweet)
Renal Involvement is Pivotal in ANCA-Associated Vasculitis Researchers have identified four different trajectories of kidney function over time in AAV patients, with implications for personalized treatment, as well as future research. https://t.co/O8EaW2MaBx https://t.co/VApYiH66yn

Links:

Dr. John Cush RheumNow ( View Tweet)
ENT involvement studied in 320 ANCA associated vasculitis pts: 65% had ENT involvement w/ median age =52 yrs, & median BVAS3 = 12. Relapse seen in 29% despite immunosupp Rx. No diff in outcomes betw pts Rx w/ oral or IV CTX or RTX https://t.co/MwZSnVVd32 https://t.co/YbrHxnqDw9

Links:

Dr. John Cush RheumNow ( View Tweet)
Systemic sclerosis current therapy: - early dcSSc: MMF, CTX, RTX, TCZ - rapidly progressive dcSSc - ?Stem cell transpl? - SSc-ILD: MMF>CTX, possibly nintedanib, perfinidone - Raynauds w/ digital ulcers: CA channel block, PDE5 inhib, iloprost, Bosentan https://t.co/87giuQR4YZ https://t.co/z2TPlJnu5e

Links:

Dr. John Cush RheumNow ( View Tweet)
Long-Term Benefit of Rituximab in Systemic Sclerosis A small cohort trial of rituximab (RTX) in 29 systemic sclerosis patients showed significantly improved skin sclerosis and lung function after a follow-up of 96 weeks. https://t.co/f68wc6lQGH https://t.co/G4PKPnJ0LJ

Links:

Dr. John Cush RheumNow ( View Tweet)
I Wanna Get Pregnant https://t.co/zOkchWO3XQ https://t.co/KhY5obavkW

Links:

Dr. John Cush RheumNow ( View Tweet)
Managing Septic Arthritis in RA https://t.co/ccRZLCtl3S https://t.co/wS2KG1jAJl

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic - Double Positive, but Few Joints Lessons from the clinic brought to you by RheumNow Live, March 18 &19, 2023 - Dallas, TX https://t.co/jnKuJbPG7l https://t.co/SiTaAXe6II

Links:

Dr. John Cush RheumNow ( View Tweet)

Recurrent Fevers; 3 Days at 103F QD Clinic - Lessons from the clinic, brought to you by RheumNow Live March 18 &19, 2023 - Dallas, TX https://t.co/pWrCVrxamD https://t.co/C6q9aVJ2gg

Links:

Dr. John Cush RheumNow ( View Tweet)
×